Wade W. Benton

1.6k total citations · 1 hit paper
22 papers, 1.2k citations indexed

About

Wade W. Benton is a scholar working on Pulmonary and Respiratory Medicine, Cardiology and Cardiovascular Medicine and Genetics. According to data from OpenAlex, Wade W. Benton has authored 22 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Pulmonary and Respiratory Medicine, 6 papers in Cardiology and Cardiovascular Medicine and 4 papers in Genetics. Recurrent topics in Wade W. Benton's work include Pulmonary Hypertension Research and Treatments (11 papers), Potassium and Related Disorders (6 papers) and Vascular Anomalies and Treatments (4 papers). Wade W. Benton is often cited by papers focused on Pulmonary Hypertension Research and Treatments (11 papers), Potassium and Related Disorders (6 papers) and Vascular Anomalies and Treatments (4 papers). Wade W. Benton collaborates with scholars based in United States, Switzerland and Germany. Wade W. Benton's co-authors include Dave P. Miller, Michael D. McGoon, Adaani Frost, Harrison W. Farber, Raymond L. Benza, David B. Badesch, Alain Romero, C. Gregory Elliott, Erwan Muros‐Le Rouzic and Abby Poms and has published in prestigious journals such as Circulation, CHEST Journal and The American Journal of Medicine.

In The Last Decade

Wade W. Benton

21 papers receiving 1.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Five-Year Outcomes of Patients Enrolled in the REVEAL Registry

2015 337 citations Harrison W. Farber, Dave P. Miller et al. CHEST Journal profile →

Peers

Countries citing papers authored by Wade W. Benton

Since Specialization

Citations

This map shows the geographic impact of Wade W. Benton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wade W. Benton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wade W. Benton more than expected).

Fields of papers citing papers by Wade W. Benton

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wade W. Benton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wade W. Benton. The network helps show where Wade W. Benton may publish in the future.

Co-authorship network of co-authors of Wade W. Benton

This figure shows the co-authorship network connecting the top 25 collaborators of Wade W. Benton. A scholar is included among the top collaborators of Wade W. Benton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wade W. Benton. Wade W. Benton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Design of CONQUEST, a novel, randomized, placebo-controlled, Phase 2b platform clinical trial to investigate new treatments for patients with early active systemic sclerosis with interstitial lung disease 2024 ·Journal of Scleroderma and Related Disorders ·Dinesh Khanna, (unknown), Shervin Assassi, Wade W. Benton, Gregory Gordon, (unknown), (unknown), Toby M. Maher	4
2	Risk of Amputation in Severe Frostbite—A Systematic Literature Review and Meta-analysis to Evaluate Iloprost and Standard of Care 2023 ·Wilderness and Environmental Medicine ·(unknown), Kyle Fahrbach, (unknown), Allison Widlitz, (unknown), Wade W. Benton, Christopher Davis	0
3	Effect of Patiromer on Hyperkalemia Recurrence in Older Chronic Kidney Disease Patients Taking RAAS Inhibitors 2017 ·The American Journal of Medicine ·Matthew R. Weir, David A. Bushinsky, Wade W. Benton, (unknown), Martha Mayo, Susan Arthur, Bertram Pitt, George L. Bakris	33
4	Evaluation of the Potential for Drug Interactions With Patiromer in Healthy Volunteers 2017 ·Journal of Cardiovascular Pharmacology and Therapeutics ·Lawrence J. Lesko, Elliot Offman, Christine Taylor Brew, Dahlia Garza, Wade W. Benton, Martha Mayo, Alain Romero, Charles Du Mond, Matthew R. Weir	27
5	Patiromer Decreases Serum Potassium and Phosphate Levels in Patients on Hemodialysis 2016 ·American Journal of Nephrology ·David A. Bushinsky, Patrick Rossignol, David M. Spiegel, Wade W. Benton, Jinwei Yuan, Geoffrey A. Block, Christopher S. Wilcox, Rajiv Agarwal	38
6	Mechanism of Action and Pharmacology of Patiromer, a Nonabsorbed Cross-Linked Polymer That Lowers Serum Potassium Concentration in Patients With Hyperkalemia 2016 ·Journal of Cardiovascular Pharmacology and Therapeutics ·Lingyun Li, Stephen D. Harrison, M. Cope, (unknown), Lawrence Lee, (unknown), (unknown), Wade W. Benton, Lance Berman, Jerry Buysse	89
7	Evaluation of clinical outcomes and costs based on prescribed dose level of renin-angiotensin-aldosterone system inhibitors. 2016 ·PubMed ·Murray Epstein, (unknown), Nancy L. Reaven, Susan E. Funk, Karen McGaughey, (unknown), Wade W. Benton, Ladan Golestaneh	20
8	Effect of Patiromer on Urinary Ion Excretion in Healthy Adults 2016 ·Clinical Journal of the American Society of Nephrology ·David A. Bushinsky, David M. Spiegel, Coleman Gross, Wade W. Benton, Jeanene Fogli, Kathleen M. Hill Gallant, Charles Du Mond, Geoffrey A. Block, Matthew R. Weir, Bertram Pitt	40
9	Five-Year Outcomes of Patients Enrolled in the REVEAL Registry breakdown → 2015 ·CHEST Journal ·Harrison W. Farber, Dave P. Miller, Abby Poms, David B. Badesch, Adaani Frost, Erwan Muros‐Le Rouzic, Alain Romero, Wade W. Benton, C. Gregory Elliott, Michael D. McGoon, Raymond L. Benza	337
10	The burden of hyperkalemia in patients with cardiovascular and renal disease. 2015 ·PubMed ·(unknown), Wade W. Benton, (unknown), (unknown)	64
11	Characterization of First-Time Hospitalizations in Patients With Newly Diagnosed Pulmonary Arterial Hypertension in the REVEAL Registry 2014 ·CHEST Journal ·Charles D. Burger, (unknown), (unknown), Michael D. McGoon, Dave P. Miller, Alain Romero, Wade W. Benton, Robert E. Safford	72
12	Predicting outcomes in pulmonary arterial hypertension based on the 6-minute walk distance 2014 ·The Journal of Heart and Lung Transplantation ·Harrison W. Farber, Dave P. Miller, Michael D. McGoon, Adaani Frost, Wade W. Benton, Raymond L. Benza	87
13	Prognostic implications of serial risk score assessments in patients with pulmonary arterial hypertension: A Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL) analysis 2014 ·The Journal of Heart and Lung Transplantation ·Raymond L. Benza, Dave P. Miller, Aimee J. Foreman, Adaani Frost, David B. Badesch, Wade W. Benton, Michael D. McGoon	103
14	Hospitalization and Survival in Patients Using Epoprostenol for Injection in the PROSPECT Observational Study 2014 ·CHEST Journal ·Robert P. Frantz, Robert Schilz, Murali M. Chakinala, David B. Badesch, Adaani Frost, Vallerie V. McLaughlin, Robyn J. Barst, D Rosenberg, Dave P. Miller, (unknown), Wade W. Benton, Harrison W. Farber	37
15	The PROSPECT Registry of Pulmonary Arterial Hypertension (PAH): Description of Patients Who Transitioned From Inhaled Prostacyclin to Intravenous Epoprostenol 2014 ·The Journal of Heart and Lung Transplantation ·Harrison W. Farber, Robert P. Frantz, Robert Schilz, Kelly Chin, D Rosenberg, (unknown), (unknown), Dave P. Miller, Wade W. Benton, Murali M. Chakinala	1
16	A Multicenter, Retrospective Study of Patients with Pulmonary Arterial Hypertension Transitioned from Parenteral Prostacyclin Therapy to Inhaled Iloprost 2013 ·Pulmonary Circulation ·Richard N. Channick, Robert P. Frantz, Steven M. Kawut, Harold I. Palevsky, Ramagopal Tumuluri, Roxana Sulica, (unknown), Wade W. Benton, (unknown)	14
17	Two formulations of epoprostenol sodium in the treatment of pulmonary arterial hypertension: EPITOME-1 (epoprostenol for injection in pulmonary arterial hypertension), a phase IV, open-label, randomized study 2013 ·American Heart Journal ·Kelly Chin, David B. Badesch, Ivan M. Robbins, Victor F. Tapson, Harold I. Palevsky, Nick H. Kim, Steven M. Kawut, Adaani Frost, Wade W. Benton, J. Lemarié, Frédéric Bodin, Lewis J. Rubin, Vallerie V. McLaughlin	21
18	Bloodstream Infection Rates in Patients With Pulmonary Arterial Hypertension Treated With Epoprostenol for Injection: A PROSPECT Registry Analysis 2012 ·CHEST Journal ·Robert P. Frantz, Murali M. Chakinala, Robyn J. Barst, Robert Schilz, Kelly Chin, Anna R. Hemnes, (unknown), Wade W. Benton, (unknown), Harrison W. Farber	1
19	The PROSPECT Registry: Study Design, Patient Characteristics, And Treatment Patterns 2012 ·Harrison W. Farber, Robert P. Frantz, Robert Schilz, Murali M. Chakinala, Wade W. Benton, Dave P. Miller, (unknown), Robyn J. Barst	2
20	Randomized trial of biofilm testing to select antibiotics for cystic fibrosis airway infection 2010 ·Pediatric Pulmonology ·Samuel M. Moskowitz, Julia Emerson, Sharon McNamara, (unknown), David M. Orenstein, Daniel Rosenbluth, Marcia Katz, Richard C. Ahrens, Douglas B. Hornick, Patricia M. Joseph, Ronald L. Gibson, Moira L. Aitken, Wade W. Benton, Jane L. Burns	59

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact